articleJournal of the American Chemical SocietyMar 26, 2014HYBRID OA

Nanoscale Metal–Organic Frameworks for the Co-Delivery of Cisplatin and Pooled siRNAs to Enhance Therapeutic Efficacy in Drug-Resistant Ovarian Cancer Cells

CHChunbai HeKLKuangda LuDLDemin LiuWLWenbin Lin

University of Chicago

PubMed
Indexed incrossrefpubmed

Abstract

Ovarian cancer is the leading cause of death among women with gynecological malignancies. Acquired resistance to chemotherapy is a major limitation for ovarian cancer treatment. We report here the first use of nanoscale metal-organic frameworks (NMOFs) for the co-delivery of cisplatin and pooled small interfering RNAs (siRNAs) to enhance therapeutic efficacy by silencing multiple drug resistance (MDR) genes and resensitizing resistant ovarian cancer cells to cisplatin treatment. UiO NMOFs with hexagonal-plate morphologies were loaded with a cisplatin prodrug and MDR gene-silencing siRNAs (Bcl-2, P-glycoprotein [P-gp], and survivin) via encapsulation and surface coordination, respectively. NMOFs protect siRNAs…

Citation impact

868
total citations
FWCI
26.04
Percentile
100%
References
31
Citations per year

Authors

4

Topics & keywords

Topics
Keywords
  • Small interfering RNA
  • Cisplatin
  • Ovarian cancer
  • Chemistry
  • Gene silencing
  • Cancer research
  • Survivin
  • Pharmacology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding